Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study

J. Tabernero, RR. Hozak, T. Yoshino, AL. Cohn, R. Obermannova, G. Bodoky, R. Garcia-Carbonero, TE. Ciuleanu, DC. Portnoy, J. Prausová, K. Muro, RW. Siegel, RJ. Konrad, H. Ouyang, SA. Melemed, D. Ferry, F. Nasroulah, E. Van Cutsem,

. 2018 ; 29 (3) : 602-609. [pub] 20180301

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu klinické zkoušky, fáze III, časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19028670

Background: The phase III RAISE trial (NCT01183780) demonstrated that the vascular endothelial growth factor (VEGF) receptor (VEGFR)-2 binding monoclonal antibody ramucirumab plus 5-fluororuracil, leucovorin, and irinotecan (FOLFIRI) significantly improved overall survival (OS) and progression-free survival (PFS) compared with placebo + FOLFIRI as second-line metastatic colorectal cancer (mCRC) treatment. To identify patients who benefit the most from VEGFR-2 blockade, the RAISE trial design included a prospective and comprehensive biomarker program that assessed the association of biomarkers with ramucirumab efficacy outcomes. Patients and methods: Plasma and tumor tissue collection was mandatory. Overall, 1072 patients were randomized 1 : 1 to the addition of ramucirumab or placebo to FOLFIRI chemotherapy. Patients were then randomized 1 : 2, for the biomarker program, to marker exploratory (ME) and marker confirmatory (MC) groups. Analyses were carried out using exploratory assays to assess the correlations of baseline marker levels [VEGF-C, VEGF-D, sVEGFR-1, sVEGFR-2, sVEGFR-3 (plasma), and VEGFR-2 (tumor tissue)] with clinical outcomes. Cox regression analyses were carried out for each candidate biomarker with stratification factor adjustment. Results: Biomarker results were available from >80% (n = 894) of patients. Analysis of the ME subset determined a VEGF-D level of 115 pg/ml was appropriate for high/low subgroup analyses. Evaluation of the combined ME + MC populations found that the median OS in the ramucirumab + FOLFIRI arm compared with placebo + FOLFIRI showed an improvement of 2.4 months in the high VEGF-D subgroup [13.9 months (95% CI 12.5-15.6) versus 11.5 months (95% CI 10.1-12.4), respectively], and a decrease of 0.5 month in the low VEGF-D subgroup [12.6 months (95% CI 10.7-14.0) versus 13.1 months (95% CI 11.8-17.0), respectively]. PFS results were consistent with OS. No trends were evident with the other antiangiogenic candidate biomarkers. Conclusions: The RAISE biomarker program identified VEGF-D as a potential predictive biomarker for ramucirumab efficacy in second-line mCRC. Development of an assay appropriate for testing in clinical practice is currently ongoing. Clinical trials registration: NCT01183780.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19028670
003      
CZ-PrNML
005      
20190816105639.0
007      
ta
008      
190813s2018 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/annonc/mdx767 $2 doi
035    __
$a (PubMed)29228087
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Tabernero, J $u Medical Oncology, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain. CIBERONC, Universitat Autònoma de Barcelona, Barcelona, Spain.
245    10
$a Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study / $c J. Tabernero, RR. Hozak, T. Yoshino, AL. Cohn, R. Obermannova, G. Bodoky, R. Garcia-Carbonero, TE. Ciuleanu, DC. Portnoy, J. Prausová, K. Muro, RW. Siegel, RJ. Konrad, H. Ouyang, SA. Melemed, D. Ferry, F. Nasroulah, E. Van Cutsem,
520    9_
$a Background: The phase III RAISE trial (NCT01183780) demonstrated that the vascular endothelial growth factor (VEGF) receptor (VEGFR)-2 binding monoclonal antibody ramucirumab plus 5-fluororuracil, leucovorin, and irinotecan (FOLFIRI) significantly improved overall survival (OS) and progression-free survival (PFS) compared with placebo + FOLFIRI as second-line metastatic colorectal cancer (mCRC) treatment. To identify patients who benefit the most from VEGFR-2 blockade, the RAISE trial design included a prospective and comprehensive biomarker program that assessed the association of biomarkers with ramucirumab efficacy outcomes. Patients and methods: Plasma and tumor tissue collection was mandatory. Overall, 1072 patients were randomized 1 : 1 to the addition of ramucirumab or placebo to FOLFIRI chemotherapy. Patients were then randomized 1 : 2, for the biomarker program, to marker exploratory (ME) and marker confirmatory (MC) groups. Analyses were carried out using exploratory assays to assess the correlations of baseline marker levels [VEGF-C, VEGF-D, sVEGFR-1, sVEGFR-2, sVEGFR-3 (plasma), and VEGFR-2 (tumor tissue)] with clinical outcomes. Cox regression analyses were carried out for each candidate biomarker with stratification factor adjustment. Results: Biomarker results were available from >80% (n = 894) of patients. Analysis of the ME subset determined a VEGF-D level of 115 pg/ml was appropriate for high/low subgroup analyses. Evaluation of the combined ME + MC populations found that the median OS in the ramucirumab + FOLFIRI arm compared with placebo + FOLFIRI showed an improvement of 2.4 months in the high VEGF-D subgroup [13.9 months (95% CI 12.5-15.6) versus 11.5 months (95% CI 10.1-12.4), respectively], and a decrease of 0.5 month in the low VEGF-D subgroup [12.6 months (95% CI 10.7-14.0) versus 13.1 months (95% CI 11.8-17.0), respectively]. PFS results were consistent with OS. No trends were evident with the other antiangiogenic candidate biomarkers. Conclusions: The RAISE biomarker program identified VEGF-D as a potential predictive biomarker for ramucirumab efficacy in second-line mCRC. Development of an assay appropriate for testing in clinical practice is currently ongoing. Clinical trials registration: NCT01183780.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a monoklonální protilátky $x terapeutické užití $7 D000911
650    _2
$a protinádorové látky imunologicky aktivní $x terapeutické užití $7 D000074322
650    _2
$a protokoly protinádorové kombinované chemoterapie $7 D000971
650    _2
$a nádorové biomarkery $x krev $7 D014408
650    _2
$a kamptothecin $x analogy a deriváty $7 D002166
650    _2
$a kolorektální nádory $x farmakoterapie $7 D015179
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a fluoruracil $7 D005472
650    _2
$a lidé $7 D006801
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a leukovorin $7 D002955
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a patologická angiogeneze $x krev $7 D009389
650    _2
$a doba přežití bez progrese choroby $7 D000077982
650    _2
$a receptory vaskulárního endoteliálního růstového faktoru $x krev $7 D040262
650    _2
$a vaskulární endoteliální růstový faktor A $x krev $7 D042461
650    _2
$a vaskulární endoteliální růstový faktor D $x krev $7 D042643
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Hozak, R R $u Oncology, Eli Lilly and Company, Indianapolis, USA.
700    1_
$a Yoshino, T $u Division of Gastrointestinal Oncology/Digestive Endoscopy, National Cancer Center Hospital East, Chiba, Japan.
700    1_
$a Cohn, A L $u Medical Oncology, Rocky Mountain Cancer Center/US Oncology, Denver, USA.
700    1_
$a Obermannova, R $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
700    1_
$a Bodoky, G $u Oncology, Szent László Hospital, Budapest, Hungary.
700    1_
$a Garcia-Carbonero, R $u Medical Oncology Department, Hospital Universitario 12 de Octubre, CNIO. CIBERONC, Universidad Complutense, Madrid, Spain.
700    1_
$a Ciuleanu, T-E $u Medical Oncology, Prof. Dr. I. Chiricuta Institute of Oncology, Cluj-Napoca, Romania.
700    1_
$a Portnoy, D C $u Oncology, West Clinic, Memphis, USA.
700    1_
$a Prausová, J $u Department of Oncology and Radiotherapy, University Hospital Motol, Prague, Czech Republic.
700    1_
$a Muro, K $u Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
700    1_
$a Siegel, R W $u Laboratory for Experimental Medicine, Eli Lilly and Company, Indianapolis, USA.
700    1_
$a Konrad, R J $u Laboratory for Experimental Medicine, Eli Lilly and Company, Indianapolis, USA.
700    1_
$a Ouyang, H $u Oncology, Eli Lilly and Company, Indianapolis, USA.
700    1_
$a Melemed, S A $u Oncology, Eli Lilly and Company, Indianapolis, USA.
700    1_
$a Ferry, D $u Oncology, Eli Lilly and Company, Indianapolis, USA.
700    1_
$a Nasroulah, F $u Oncology, Eli Lilly and Company, Argentina.
700    1_
$a Van Cutsem, E $u Digestive Oncology, University Hospital Gasthuisberg, Leuven, Belgium. KU Leuven, Leuven, Belgium.
773    0_
$w MED00000432 $t Annals of oncology : official journal of the European Society for Medical Oncology $x 1569-8041 $g Roč. 29, č. 3 (2018), s. 602-609
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29228087 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190813 $b ABA008
991    __
$a 20190816105909 $b ABA008
999    __
$a ok $b bmc $g 1433819 $s 1067130
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 29 $c 3 $d 602-609 $e 20180301 $i 1569-8041 $m Annals of oncology $n Ann Oncol $x MED00000432
LZP    __
$a Pubmed-20190813

Najít záznam

Citační ukazatele

Možnosti archivace